EA202191543A1 - Способы лечения или профилактики подагры или гиперурикемии - Google Patents

Способы лечения или профилактики подагры или гиперурикемии

Info

Publication number
EA202191543A1
EA202191543A1 EA202191543A EA202191543A EA202191543A1 EA 202191543 A1 EA202191543 A1 EA 202191543A1 EA 202191543 A EA202191543 A EA 202191543A EA 202191543 A EA202191543 A EA 202191543A EA 202191543 A1 EA202191543 A1 EA 202191543A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hyperuricemia
prevention
treatment
methods
guge
Prior art date
Application number
EA202191543A
Other languages
English (en)
Inventor
Шуньци Янь
Литаин Йех
Жунцзы Янь
Original Assignee
Артроси Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Артроси Терапьютикс, Инк. filed Critical Артроси Терапьютикс, Инк.
Publication of EA202191543A1 publication Critical patent/EA202191543A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)

Abstract

В настоящем документе описаны способы лечения или профилактики подагры или гиперурикемии, предусматривающие введение (3,5-дибром-4-гидроксифенил)(2-(1-гидроксиэтил)бензофуран-3-ил-4,5,6,7-d4)метанона и его сольватов.
EA202191543A 2018-12-06 2019-12-05 Способы лечения или профилактики подагры или гиперурикемии EA202191543A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862776251P 2018-12-06 2018-12-06
PCT/US2019/064785 WO2020118114A1 (en) 2018-12-06 2019-12-05 Methods for treating or preventing gout or hyperuricemia

Publications (1)

Publication Number Publication Date
EA202191543A1 true EA202191543A1 (ru) 2021-10-26

Family

ID=70974386

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191543A EA202191543A1 (ru) 2018-12-06 2019-12-05 Способы лечения или профилактики подагры или гиперурикемии

Country Status (13)

Country Link
US (1) US20220023251A1 (ru)
EP (1) EP3890722A4 (ru)
JP (1) JP2022510303A (ru)
KR (1) KR20210102933A (ru)
CN (1) CN113164439A (ru)
AU (1) AU2019392750A1 (ru)
BR (1) BR112021010720A2 (ru)
CA (1) CA3121624A1 (ru)
EA (1) EA202191543A1 (ru)
IL (1) IL283665A (ru)
SG (1) SG11202105743RA (ru)
TW (1) TW202038936A (ru)
WO (1) WO2020118114A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113214198B (zh) 2016-07-18 2022-12-23 广州瑞安博医药科技有限公司 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
CN113368032A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 药物组合物、口服固体制剂及其制备方法和用途
WO2023098872A1 (en) * 2021-12-02 2023-06-08 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
WO2023125667A1 (en) * 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5820269B2 (ja) * 2008-05-22 2015-11-24 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
US9725430B2 (en) * 2013-01-16 2017-08-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
CA2907079C (en) * 2013-03-15 2021-06-22 Janssen Pharmaceutica Nv Combination of canagliflozin and probenecid for the treatment of hyperuricemia
CN113214198B (zh) * 2016-07-18 2022-12-23 广州瑞安博医药科技有限公司 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法

Also Published As

Publication number Publication date
SG11202105743RA (en) 2021-06-29
AU2019392750A1 (en) 2021-07-15
BR112021010720A2 (pt) 2021-08-31
IL283665A (en) 2021-07-29
US20220023251A1 (en) 2022-01-27
CN113164439A (zh) 2021-07-23
CA3121624A1 (en) 2020-06-11
KR20210102933A (ko) 2021-08-20
JP2022510303A (ja) 2022-01-26
EP3890722A4 (en) 2022-08-24
EP3890722A1 (en) 2021-10-13
WO2020118114A1 (en) 2020-06-11
TW202038936A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
EA202191543A1 (ru) Способы лечения или профилактики подагры или гиперурикемии
EA202191545A1 (ru) Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии
JOP20200209A1 (ar) مثبطات cd73
EA201790174A1 (ru) Антипролиферативные соединения и способы их применения
EA201800444A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
CY1124088T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
EA201890199A1 (ru) Комбинированная терапия для лечения гемобластозов и солидных опухолей
PH12021550542A1 (en) Multivalent pneumococcal vaccines
EA202191519A1 (ru) Модуляторы trex1
CL2022000531A1 (es) Composiciones y métodos para el tratamiento de infecciones virales.
DK3866772T3 (da) 2,3,5-trimethyl-6-nonylcyclohexa-2,5-dien-1,4-dion til undertrykkelse og behandling af alpha-synucleinopathier, tauopathier og andre lidelser
DK3759083T3 (da) 2,4-diaminoquinazolinderivater og anvendelse deraf til behandling af virusinfektioner, cancer eller allergier
EA202092748A1 (ru) Модуляторы экспрессии apol1
DK3752506T3 (da) Pyrimidinderivater til forebyggelse og behandling af bakterielle infektioner
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
UY38352A (es) Inhibidores de integrina alfavbeta6
ZA202103975B (en) Methods of treating disease with magl inhibitors
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
EA202090194A1 (ru) Композиции статинов и способы их применения при лечении синуклеинопатий
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
EA202192101A1 (ru) Соединения и их применение
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
EA201792318A1 (ru) Специфический аналог трифторэтилхинолина для применения при лечении синдрома шегрена
EA202091821A1 (ru) Ингибиторы cd73